Super Purchasing for Lanreotide Acetate Gmp Supplier - Bivalirudin for injection – JYMed

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We keep on with our enterprise spirit of "Quality, Efficiency, Innovation and Integrity". We intention to create extra worth for our buyers with our prosperous resources, superior machinery, experienced workers and superb services for Octreolin, Vasporessin, Glp-1(7-37) Acetate, We sincerely hope to determine some satisfactory interactions with you in the in the vicinity of long term. We'll hold you informed of our progress and stay up for building steady small business relations along with you.
Super Purchasing for Lanreotide Acetate Gmp Supplier - Bivalirudin for injection – JYMed Detail:

Bivalirudin for injection

250mg/vial   Strength

Indication: Bivalirudin is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).

Clinical application:It is usedfor intravenous injection and intravenous drip.

INDICATIONS AND USAGE

1.1 Percutaneous Transluminal Coronary Angioplasty (PTCA)

Bivalirudin for Injection is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).

1.2 Percutaneous Coronary Intervention (PCI)

Bivalirudin for Injection with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) as listed in the

REPLACE-2 trial is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).

Bivalirudin for Injection is indicated for patients with, or at risk of, heparin induced thrombocytopenia (HIT) or heparin induced thrombocytopenia and thrombosis syndrome (HITTS) undergoing PCI.

1.3 Us e with Aspirin

Bivalirudin for Injection in these indications is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

1.4 Limitation of Use

The safety and effectiveness of bivalirudin for injection have not been established in patients with acute coronary syndromes who are not undergoing PTCA or PCI.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

Bivalirudin for Injection is for intravenous administration only.

Bivalirudin for Injection is intended for use with aspirin (300 to 325 mg daily) and has been studied only in patients receiving concomitant aspirin.

For patients who do not have HIT/HITTS

The recommended dose of bivalirudin for injection is an intravenous (IV) bolus dose of 0.75 mg/kg, followed immediately by an infusion of 1.75 mg/kg/h for the duration of the PCI/PTCA procedure. Five min after the bolus dose has been administered, an activated clotting time (ACT) should be performed and an additional bolus of 0.3 mg/kg should be given if needed.

GPI administration should be considered in the event that any of the conditions listed in the REPLACE-2 clinical trial description is present.

For patients who have HIT/HITTS

The recommended dose of bivalirudin for injection in patients with HIT/HITTS undergoing PCI is an IV bolus of 0.75 mg/kg. This should be followed by a continuous infusion at a rate of 1.75 mg/kg/h for the duration of the procedure.

For ongoing treatment post procedure

Bivalirudin for injection infusion may be continued following PCI/PTCA for up to 4 hours post procedure at the discretion of the treating physician.

In patients with ST segment elevation myocardial infarction (STEMI) continuation of the bivalirudin for injection infusion at a rate of 1.75 mg/kg/h following PCI/PTCA for up to 4 hours post-procedure should be considered to mitigate risk of stent thrombosis.

After four hours, an additional IV infusion of bivalirudin for injection may be initiated at a rate of 0.2 mg/kg/h (low-rate infusion), for up to 20 hours, if needed.

2.2 Dosing in Renal Impairment

No reduction in the bolus dose is needed for any degree of renal impairment. The infusion dose of bivalirudin for injection may need to be reduced, and anticoagulant status monitored in patients with renal impairment. Patients with moderate renal impairment (30 to 59 mL/min) should receive an infusion of 1.75 mg/kg/h. If the creatinine clearance is less than 30 mL/min, reduction of the infusion rate to 1 mg/kg/h should be considered. If a patient is on hemodialysis, the infusion rate should be reduced to 0.25 mg/kg/h.

2.3 Instructions for Administration

Bivalirudin for Injection is intended for intravenous bolus injection and continuous infusion after reconstitution and dilution. To each 250 mg vial, add 5 mL of Sterile Water for Injection, USP. Gently swirl until all material is dissolved. Next, withdraw and discard 5 mL from a 50 mL infusion bag containing 5% Dextrose in Water or 0.9% Sodium Chloride for Injection. Then add the contents of the reconstituted vial to the infusion bag containing 5% Dextrose in Water or 0.9% Sodium Chloride for Injection to yield a final concentration of 5 mg/mL (e.g., 1 vial in 50 mL; 2 vials in 100 mL; 5 vials in 250 mL). The dose to be administered is adjusted according to the patient’s weight (see Table 1).

If the low-rate infusion is used after the initial infusion, a lower concentration bag should be prepared. In order to prepare this lower concentration, reconstitute the 250 mg vial with 5 mL of Sterile Water for Injection, USP. Gently swirl until all material is dissolved. Next, withdraw and discard 5 mL from a 500 mL infusion bag containing 5% Dextrose in Water or 0.9% Sodium Chloride for Injection. Then add the contents of the reconstituted vial to the infusion bag containing 5% Dextrose in Water or 0.9% Sodium chloride for Injection to yield a final concentration of 0.5 mg/mL. The infusion rate to be administered should be selected from the right-hand column in Table 1.


Product detail pictures:

Super Purchasing for Lanreotide Acetate Gmp Supplier - Bivalirudin for injection – JYMed detail pictures


Related Product Guide:
Form 20-F Galmed Pharmaceuticals For: Dec 31 | Trelstar(Triptorelin Pamoate)
ADP-ribose/TRPM2-mediated Ca2+ signaling is essential for cytolytic degranulation and antitumor activity of natural killer cells | Terlipressin Acetate Gmp Manufacturer

Our products are widely recognized and trusted by users and can meet continuously developing economic and social needs for Super Purchasing for Lanreotide Acetate Gmp Supplier - Bivalirudin for injection – JYMed , The product will supply to all over the world, such as: Brasilia, Oman, Turkey, As an experienced manufacturer we also accept customized order and we could make it the same as your picture or sample specification. The main goal of our company is to live a satisfactory memory to all the customers, and establish a long term business relationship with buyers and users all over the world.
  • In China, we have many partners, this company is the most satisfying to us, reliable quality and good credit, it is worth appreciation.
    5 Stars By Louise from Norway - 2016.08.15 12:36
    Sales manager is very enthusiastic and professional, gave us a great concessions and product quality is very good,thank you very much!
    5 Stars By Laura from Saudi Arabia - 2015.08.12 12:27
    Write your message here and send it to us